Zimmer Biomet (NYSE:ZBH) Insider Kevin Thornal Sells 5,691 Shares of Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Kevin Thornal sold 5,691 shares of Zimmer Biomet stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $98.45 on Wednesday. The stock has a market cap of $18.78 billion, a price-to-earnings ratio of 23.95, a PEG ratio of 1.82 and a beta of 0.47. The company has a quick ratio of 0.94, a current ratio of 1.69 and a debt-to-equity ratio of 0.50. The business has a 50-day simple moving average of $95.86 and a 200 day simple moving average of $91.44. Zimmer Biomet Holdings, Inc. has a 52 week low of $79.12 and a 52 week high of $106.88.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.06. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%.The company’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $2.07 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is presently 23.36%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ZBH. Zacks Research upgraded shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. Stifel Nicolaus boosted their target price on Zimmer Biomet from $105.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Sanford C. Bernstein upped their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets reissued a “market perform” rating and set a $96.00 price target on shares of Zimmer Biomet in a research note on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $104.42.

Institutional Trading of Zimmer Biomet

Several large investors have recently modified their holdings of ZBH. OMERS ADMINISTRATION Corp purchased a new stake in Zimmer Biomet during the 2nd quarter valued at about $922,000. Hsbc Holdings PLC purchased a new position in Zimmer Biomet in the second quarter worth about $35,417,000. PNC Financial Services Group Inc. lifted its stake in shares of Zimmer Biomet by 9.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 161,195 shares of the medical equipment provider’s stock worth $14,495,000 after buying an additional 13,883 shares in the last quarter. Morningstar Investment Management LLC grew its holdings in shares of Zimmer Biomet by 235.4% during the fourth quarter. Morningstar Investment Management LLC now owns 57,865 shares of the medical equipment provider’s stock valued at $5,204,000 after buying an additional 40,610 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Zimmer Biomet during the second quarter valued at approximately $126,167,000. 88.89% of the stock is owned by institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.